# Aptevo Therapeutics (APVO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/APVO
## Company Profile
- Ticker: APVO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology, Hematology
## Stock Data
- Close: 1.71 USD
- Market cap: 6280369.2 USD
- Last updated: 2026-09-03
## Business Overview
### Multispecific Immunotherapy Platforms
Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct.
### Mipletamig
Mipletamig is a bispecific antibody candidate designed to redirect T cells toward CD123-expressing leukemia cells. Aptevo is developing the program in frontline acute myeloid leukemia in combination with venetoclax and azacitidine.
### RAINIER Frontline AML Study
RAINIER is a Phase 1b/2 study evaluating mipletamig with venetoclax and azacitidine in newly diagnosed AML. The Phase 1b portion is focused on dose optimization and selection of a recommended Phase 2 dose before the program advances into a larger expansion stage.
### APVO451
APVO451 is a trispecific solid-tumor candidate directed at nectin-4 and designed to engage immune effector mechanisms. The program is in candidate-selection work ahead of IND-enabling development.
### Radiopharmaceutical Collaboration
Aptevo is also working with Niowave under a 50-50 collaboration to develop radiopharmaceutical oncology programs. The partnership combines Aptevo's multispecific binding constructs with Niowave's radioisotope capabilities and may encompass as many as three programs.
## Why The Stock Is Moving

Following the latest company update, “Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML”, APVO closed down 34.2% at $1.71 on Sep 3, 2026. The move occurred in the trading session associated with this company update.

## Future Catalysts

- Completion of RAINIER Phase 1b and selection of the recommended Phase 2 dose for mipletamig by year-end 2026.
- Selection of the APVO451 development candidate by year-end 2026.
- Regulatory interaction regarding the mipletamig Phase 2 program in Q1 2027.
- Initiation of IND-enabling studies for APVO451 in Q1 2027.

## Recent News
- 2026-09-03 12:05 EST — [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML](https://biopharmsignal.com/news/APVO/aptevo-reports-93-clinical-benefit-rate-with-mipletamig-triplet-in-difficult-to--ae677d78) — Source: Aptevo Therapeutics
- 2026-08-14 12:05 EST — [Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results](https://biopharmsignal.com/news/APVO/aptevo-provides-2q26-business-update-and-reports-second-quarter-financial-result-38b7460d) — Source: Aptevo Therapeutics
- 2026-08-13 20:05 EST — [Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-announces-closing-of-existing-warrants-exercise-and-pipe-for-34d653f8) — Source: Aptevo Therapeutics
- 2026-08-12 13:30 EST — [Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-announces-exercise-of-existing-warrants-and-pipe-for-4-5-mil-e6ca5124) — Source: Aptevo Therapeutics
- 2026-07-27 12:05 EST — [Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone](https://biopharmsignal.com/news/APVO/aptevo-strengthens-solid-tumor-strategy-with-patent-filing-for-nectin-4-x-pd-l1--2cdf8d86) — Source: Aptevo Therapeutics